ArticleNutrition & metabolism2026
Effects of Japan tallow on gut microbiota in type 2 diabetic mice.
Article in Nutrition & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBlack Japan tallow (BJT) and white Japan tallow (WJT), collectively referred to as Japan tallow (JT), are traditional edible oils widely consumed in the Nujiang region of Yunnan, China. JT has been traditionally used for its potential health benefits, including anti-diabetic effects. However, scientific evidence supporting these claims is limited, and the underlying mechanisms remain unclear. This study aimed to evaluate the anti-diabetic effects of JT and to explore whether its action involves modulation of the gut microbiota.
methodsThe lipidomic profile of JT was first characterized. Thirty C57BL/6J mice were randomly divided into five groups (n = 6): control group (ND), T2DM group (T2DM), dietary intervention group (CTRL), metformin treatment group (MET), and JT intervention group (JT). T2DM was induced by a high-fat diet (HFD) combined with low-dose streptozotocin (STZ) injections in all groups except ND. Body weight, food intake and fasting blood glucose (FBG) were monitored weekly. Metabolic responses were assessed using oral glucose tolerance test (OGTT) and insulin tolerance test (ITT). After four weeks, fecal samples were collected for 16 S rDNA sequencing, and tissue samples from the colorectum, liver, and pancreas were harvested for histological analysis.
resultsLipidomic analysis identified 230 distinct lipid molecules in JT. BJT showed higher abundances of unsaturated ceramide (Cer t18:1_22:1) and OAHFA (42:7). JT intervention significantly improved glycemic control, enhanced insulin sensitivity, and ameliorated tissue damage in the colorectum, liver, and pancreas of T2DM mice. Furthermore, 16 S rDNA sequencing indicated that JT intervention restored gut microbiota balance, shifting its composition toward a healthy state.
conclusionJT exhibits significant anti-diabetic effects in a mouse model of T2DM, likely mediated through the restoration of gut microbiota homeostasis and improvement of metabolic parameters. These findings provide experimental support for the traditional use of JT and form a basis for future studies on its translational potential.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.